Everolimus for Advanced Pancreatic Neuroendocrine Tumors

10.1245/s10434-007-9566-6

10.1200/JCO.2007.15.4377

10.1200/JCO.2009.24.2669

Broder LE, 1973, Ann Intern Med, 79, 108, 10.7326/0003-4819-79-1-108

Chernicoff D, 1979, Cancer Treat Rep, 63, 795

10.1056/NEJM198011203032101

10.1056/NEJM199202203260804

10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P

10.1586/14737140.3.5.631

10.1200/JCO.2004.04.024

10.1097/01.coc.0000135343.06038.eb

10.1023/A:1011632713360

10.1002/cncr.23648

10.1016/j.ejca.2003.09.035

10.1056/NEJMoa1003825

10.1200/JCO.2008.16.7858

10.1200/JCO.2007.14.0988

von Wichert G, 2000, Cancer Res, 60, 4573

10.1677/ERC-07-0202

10.1200/JCO.2008.21.5988

10.1093/jnci/92.3.205

10.1097/00000421-198212000-00014

Bushnell W. An overview of independent review of PFS and proposal for an audit methodology. Presented at the Conference on Clinical Cancer Research, Washington, DC, September 14, 2009. (http://www.brookings.edu/~/media/Files/events/2009/0914_clinical_cancer_research/Panel2ApresFINAL.pdf.)

Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2008:1702-21.

10.1016/S0140-6736(08)61039-9